Dong et al., 2020 - Google Patents
Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotypeDong et al., 2020
View HTML- Document ID
- 6138194322201087030
- Author
- Dong H
- Yang Y
- Gao C
- Sun H
- Wang H
- Hong C
- Wang J
- Gong F
- Gao X
- Publication year
- Publication venue
- Journal for immunotherapy of cancer
External Links
Snippet
Background Tumor-associated macrophages (TAMs) resemble M2-polarized cells with potent immunosuppressive activity and play a pivotal role in tumor growth and progression. Converting TAMs to proinflammatory M1-like phenotype is thus an attractive strategy for …
- 229940078795 Lactoferrin 0 title abstract description 62
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dong et al. | Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype | |
| Zhang et al. | CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner | |
| Wang et al. | CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy | |
| Bailey et al. | Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence | |
| Di Blasio et al. | Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death | |
| Demaria et al. | Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant | |
| Hay et al. | Targeting CD73 in the tumor microenvironment with MEDI9447 | |
| Wu et al. | Glioma cancer stem cells induce immunosuppressive macrophages/microglia | |
| Banchereau et al. | The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming | |
| Szajnik et al. | Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg) | |
| Sierra et al. | Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation | |
| Wachstein et al. | HSP70 enhances immunosuppressive function of CD4+ CD25+ FoxP3+ T regulatory cells and cytotoxicity in CD4+ CD25− T cells | |
| Wong et al. | Synergistic COX2 induction by IFNγ and TNFα self-limits type-1 immunity in the human tumor microenvironment | |
| Sagnella et al. | Cyto-immuno-therapy for cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells | |
| Niu et al. | In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells | |
| Wu et al. | TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo | |
| Budhu et al. | Targeting phosphatidylserine enhances the anti-tumor response to tumor-directed radiation therapy in a preclinical model of melanoma | |
| Gao et al. | Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2-into M1-like phenotype | |
| Agrawal et al. | Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses | |
| Ma et al. | Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer | |
| Ferrari et al. | Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I | |
| Sabree et al. | Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist | |
| Kubach et al. | IgG1 anti‐epidermal growth factor receptor antibodies induce CD8‐dependent antitumor activity | |
| JP6712262B2 (en) | Cell populations for use in immunotherapy | |
| Nakazawa et al. | Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors |